Dr Reddy’s Laboratories, a second largest Indian pharma giant, has launched zoledronic acid injection (5 mg/100 mL), a therapeutic equivalent generic version of Reclast (zoledronic acid) injection 5 mg/100 mL in the US market on April 03, 2013, following the approval by the United States Food & Drug Administration (US FDA) of Dr Reddy’s ANDA for zoledronic acid injection (5 mg/100 mL).

The Reclast brand had total US sales of approximately $355 million for the most recent twelve months ending February 2013 according to IMS Health.

Dr Reddy’s zoledronic acid injection (5 mg/100 mL) is available in a single use vial for intravenous infusion.